The purpose of this study is to evaluate the feasibility of contingency management on improving smoking cessation among individuals with type 2 diabetes.
Type 2 diabetes (T2DM) and cigarette smoking are major causes of morbidity and mortality in US, and research indicates there is a complex relationship between these two risk factors. Smoking cessation is recommended as a standard treatment of diabetes by the American Diabetes Association; however, patients with T2DM and their providers are often inundated with other challenging lifestyle changes and disease management. Due to the complex relationship between diabetes and smoking and the large number of competing lifestyle changes recommended at diagnosis, smokers with T2DM may benefit from a contingency management (CM) program that incentivizes cessation. Providing patients tangible rewards to reinforce positive behaviors such as smoking abstinence has been proven effective in substance abuse programs, smoking cessation among pregnant women unwilling or unable to quit, and other population subgroups. In this CRUK2 study the investigators aim to test and further explore the potential effectiveness of financial incentives contingent upon proof of quitting smoking. The investigators will gather diabetes-related contextual factors associated with participation in the program and smoking cessation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
29
Escalating financial incentives contingent upon biochemical evidence of abstinence
Usual care smoking cessation support
Oklahoma Tobacco Research Center
Oklahoma City, Oklahoma, United States
Number of participants completing 6 study visits
Feasibility outcome: completion of 6 study visits
Time frame: 5 weeks
Number of participants with >80% completion of daily ecological momentary assessments (EMA) completed
Feasibility outcome: completion of EMA portion of study
Time frame: 4 weeks
Number of participants with biochemically verified abstinence at 4 weeks post quit
Carbon Monoxide (CO) ≤ 6 ppm on exit date; self-reported 7-day point prevalence abstinence
Time frame: 5 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.